Ticker: MRIC Investor Presentation

MRIC Investor Presentation March 23, 2016 Transforming minimally invasive neurosurgery by enabling real-time visualization

with MRI 2015 MRI INTERVENTIONS, INC. | 1

Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section

27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can

be identified by words such as "anticipates," "believes," "could," "estimates," "expects,"

"intends," "may," "plans," "potential," "predicts," "projects," "should,"

"will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements

by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause

MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions'

forward-looking statements. Particular uncertainties and risks include, among others: demand and market acceptance of our products;

our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities;

availability and adequacy of reimbursement from third party payors for procedures utilizing our products; the sufficiency of our

cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA

or any other regulatory body that could impact product development, manufacturing or sale; our ability to protect and enforce

our intellectual property rights; our dependence on collaboration partners; the impact of competitive products and pricing; the

impact of the commercial and credit environment on us and our customers and suppliers; and our ability to successfully complete

the development of, and to obtain regulatory clearance or approval for, our ClearTrace system. More detailed information on these

and additional factors that could affect MRI Interventions' actual results and the timing of events are described in its filings

with the Securities and Exchange Commission. Except as required by law, MRI Interventions undertakes no obligation to publicly

update or revise any forward-looking statements made in this presentation to reflect any change in MRI Interventions' expectations

or any change in events, conditions or circumstances on which any such statements are based.

2015 MRI INTERVENTIONS, INC. | 2

Interventions Opportunity Market potential Market Potential 55,000 potential ClearPoint procedures across multiple therapies Electrode

placement for deep brain stimulation Navigation System Laser Ablation for ablation of epileptic foci or Brain Tumors

for Multiple Brain Tumor Biopsy for deep seated tumors Therapies Precise Drug Delivery to target lesions Opportunity

to Area of interest to large medical device companies Attract Multiple Medtronic, St. Jude and Boston Scientific investing in

neuro market Players MRI Scanner Companies embracing MRI-guided therapies Drug Companies pursuing direct delivery Focused commercial

effort in neurosurgery; FDA/CE approved products Uniquely Delivery platform for multiple therapies Positioned Established, proprietary

IP position Recent restructuring complete 2015 MRI INTERVENTIONS, INC. | 3

Interventions: Real Time MRI Guided Surgery First- market technology platform enabling time MRI guided surgery; FDA cleared, CE

marked and 40+ ClearPoint sites Focused commercialization of neuro platform underway; ecent restructuring complete Attractive

razor/razorblade business model with strong potential margins Compatible with all major MRI manufacturers; Interoperability w/

Medtronic, Monteris, neuro roducts Established intellectual property portfolio Professional management team with relevant medical

device commercialization experience: Intuitive, Medtronic, Kyphon, Boston Scientific, ev3, Edwards Lifescience, Cordis

2015 MRI INTERVENTIONS, INC. | 4

A History of Med Device Experience Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi

COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip

Pizzo Pascal Girin Timothy Frank Grillo, Exec Chair Richards CEO Spencer Charles Koob Andrew Rooke Major Investor 2015 MRI INTERVENTIONS,

ClearPoint Neuro Navigation System Navigation System consisting of Integrated Devices and Software for Real-Time, MRI

Guided, Minimally Invasive Neurosurgical Procedures Visualize Verify Confirm Identify target Observe progress to target Confirm

precise placement at target 2015 MRI INTERVENTIONS, INC. | 6

ClearPoint, minimally invasive neuro Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real-time visualization

Next generation platform enabling real time, MRI guided, minimally invasive brain surgery 2015 MRI INTERVENTIONS, INC.

Neuro Navigation System 1.5T or 3T MR Scanners, also works in intraop MRI Suites MRI Safe Disposable Components: SmartGrid

and SmartFrame Integrated ClearPoint Targeting and Trajectory Precision ClearPoint Drape provides sterile procedural

field in any diagnostic or intraoperative MRI scanner Emory University Hospital UCSF Medical Center University of Pittsburgh sOSAw AYE t wGY Medical Center Hospital* * Image courtesy of IMRIS Integrates with All Major Scanner Platforms 2015

MRI INTERVENTIONS, INC. | 8

Procedure Overview Target Selection & Entry Planning 2015 MRI INTERVENTIONS, INC. | 9

Procedure Overview Trajectory Alignment & Device Insertion SmartFrame Hand Controller 2015 MRI INTERVENTIONS,

Procedure Overview Delivery of Neurological Therapy Drug Delivery1 Electrode Placement Laser Ablation2 (1)

Drug Delivery - The SmartFlow cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the

ventricles or removal of CSF from the ventricles during intracranial procedures. Delivery of other therapeutic agents, and delivery

of agents to other areas of the brain, using the SmartFlow cannula is investigational. (2) Laser Ablation - MR Thermometry is

an MRI-based functionality available on most MR scanner platforms and it is a feature built into products from several third party

vendors. The ClearPoint system enables MRI-guided procedures and allows physicians to use this inherent MR capability during a

procedure. 2015 MRI INTERVENTIONS, INC. | 11

Hospital Economics Increase Patients Better potential patient experience provides hospitals the opportunity to reach additional

patient populations that may otherwise forego surgery 65% of eligible DBS patients refuse treatment, due to fear of surgery(1)

Established, Attractive Reimbursement Move procedures from the more expensive OR to the less expensive MR suite, with equivalent

reimbursement Improved Utilization of s lsYO DZ/ 1 hour of MR Scanner time used for diagnostic imaging could generate $1,200(2)

1 hour of MR scanner time used for a ClearPoint procedure could generate $5,275(3) hlsus G G s lsYO DZ/ Au GAE sY S slAu

(1) Medtronic Investor Presentation, June, 2014 (2) Estimated average US hospital-based MRI suite revenue per hour for outpatient

diagnostic scans, based on data gathered by MRI Interventions. Excludes professional fees. Actual revenues will vary by hospital,

procedure and payor. (3)A GE Y A GsOSlGE A|G AOG A wGYl l DZ/ /YlG |GYls Y l wG ;A I

^G lGwdG I AY GuG l EG uA GwGYl Gdure for Medicare and private insurance patients,

calculated by MRI Interventions using a payor mix weighted 67% to average Medicare reimbursement and 33% to average private insurance

reimbursement. Average Medicare reimbursement calculated as lSG GsOSlGE A|G AOG DGEs A G A wGYl I DZ/ /YlG |GYls Y

l wG ;A I "width: 33% I AY GuG l EG uA GwGYl edure under MS-DRGs

025, 026 and 027. Average private insurance reimbursement calculated as 1.5x Medicare reimbursement, based on published data.

Hourly amount assumes 4.5 hour procedure duration. Excludes professional fees. Actual revenues will vary by hospital, procedure

and payor. 2015 MRI INTERVENTIONS, INC. | 12

MRI-Guided Navigational System Notable Neurosurgeon Supporters Dr. Philip Starr Dr. Paul Larson Dr. Robert Gross Dr. Robert Wharen,

Jr. ASSFN Past President UCSF & VA Emory University Mayo Clinic -Jacksonville Published Peer-Reviewed Journal Support Compatible

With Multiple Therapies Visualase(R) 6PDUW)ORZ cannula for local drug delivery 2015 MRI INTERVENTIONS, INC. | 13

Intellectual Property Close to 100 issued patents around the world 40+ U.S. 50+ OUS 50+ U.S. Patents 45+ OUS Patents Patent

Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software

and devices; the SmartFrame trajectory guide; other ClearPoint disposable components; active intracranial probes; MRI-compatible

catheters and Hand Drill; MRI-safety technology; Scalp Mount Base Key ClearPoint-related patents do not begin to expire until

2027 2015 MRI INTERVENTIONS, INC. | 14

Impact D _^ C l e a r Po i nt - E n a b l e d E l e c t ro d e P l a c e m e nt 2015 MRI INTERVENTIONS, INC. | 15

Benefit Minimally Invasive Procedure 7 days after ClearPoint procedure Arrow Indicates Surgery Site INC. | 16

Drug Delivery MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered under MR-guidance*

6SHFLDOL]HG_GUXJ_GHOLYHU_FDQQXOD V___FDWKHWHUV Conclusion: The ClearPoint system allows Real-time Convection-enhanced

Delivery to be performed with a high level of precision, predictability, and safety. Drug infusion is visible real time under

MRI &$87,21__6PDUW)ORZ&DQQXOD_LV_DSSURYHG__IRU__LQMHFWLRQ_RI&\WDUDELQH_RU_UHPRYDO_RI_&6)_IURP_WKH_YHQWULFOHV_GXULQJ_LQWUDFUDnial

procedures. 2015 MRI INTERVENTIONS, INC. | 17 Uses other than the approved indication are limited by Federal law to investigational

_h _K _ __ _ Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery of almost

all drugs up to 98% of small molecules - Direct injection without ClearPoint is blind, so target can frequently be missed - Neopharm

Trial - 51% of 572 catheters failed to meet all positioning criteria Major Benefits of Drug Delivery with ClearPoint

- Neurosurgeon can see that target is reached - Eliminates the blood brain barrier issue; Reduces/eliminates unwanted systemic

side effects; Reduces dosage levels (as little as 1/300th of systemic volumes) Business Model MRIC Partners with Drug Companies

and Researchers - MRIC provides ClearPoint; Drug company provides drug candidate - Drug company/sponsor pays for trial - If drug

is approved, MRIC gets device revs (~$7000/case); Drug co gets drug revs 2015 MRI INTERVENTIONS, INC. | 18

ClearPoint Difference Without ClearPoint (Stereotactic) With ClearPoint room an MRI Suite Accuracy to target based on prior images

Highly accurate, based on real time images Patient may be awake for own brain surgery(1) Patient may be under general anesthesia(1)

Long OR time for the patient Can be up to 8 hours Shorter procedures Can be 3 hours or less May require OR and MRI for same

procedure (laser MRI only procedure - One procedure, one place ablation) Poor economics for hospital and physician Attractive

economics for hospital and physician Better for Patients Better for Surgeons Better for Hospitals (1) Microelectrode recording

and macrostim are processes that involve listening to neuronal firings (i.e., physiological recordings) and observing physiological

responses to stimuli _ _ / _ _ _ _ _ _ _ _ & _ _ _ __ W _/ uctions for Use based on the lack of data with respect to